Announcements Trials

Conditions

Plasma cell 1

Drug Classes

Anti-CD38 15Proteasome inhibitor 11Immunomodulatory drugs (IMiDs) 8Anti-BCMA-CD3 bispecific 4Anti-BCMA CAR T-cell 2Anti-BCMA ADC 2XPO1 inhibitor 2Anti-GPRC5D-CD3 bispecific 1
Anti-GPRC5D-CD3 bispecific × Plasma cell × Clear all

1 Announcement

2023-08-09

FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma

Trials
MonumenTAL-1, MonumenTAL-1
Drug
Talvey (talquetamab-tgvs) · Anti-GPRC5D-CD3 bispecific antibody
Condition
Plasma cell
Data powered by HemOnc (CC BY 4.0) Colophon âš¡